ES2548513T3 - Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa - Google Patents

Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa Download PDF

Info

Publication number
ES2548513T3
ES2548513T3 ES12742957.9T ES12742957T ES2548513T3 ES 2548513 T3 ES2548513 T3 ES 2548513T3 ES 12742957 T ES12742957 T ES 12742957T ES 2548513 T3 ES2548513 T3 ES 2548513T3
Authority
ES
Spain
Prior art keywords
piperidin
oxo
methoxy
benzoyl
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12742957.9T
Other languages
English (en)
Spanish (es)
Inventor
Christine Hiu-Tung Chen
Noel Chin CHIN
Lucian V. Dipietro
Jianme FAN
Mark G Palermo
Michael David SHULTZ
Bakary-Barry Toure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2548513T3 publication Critical patent/ES2548513T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES12742957.9T 2011-07-13 2012-07-13 Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa Active ES2548513T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
US201161507321P 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (1)

Publication Number Publication Date
ES2548513T3 true ES2548513T3 (es) 2015-10-19

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12742957.9T Active ES2548513T3 (es) 2011-07-13 2012-07-13 Compuestos de 4-piperidinilo para uso como inhibidores de tankirasa

Country Status (21)

Country Link
US (2) USRE46942E1 (enExample)
EP (1) EP2731940B1 (enExample)
JP (1) JP5957077B2 (enExample)
KR (1) KR20140051944A (enExample)
CN (1) CN103797006B (enExample)
AP (1) AP2014007400A0 (enExample)
AU (1) AU2012282076A1 (enExample)
BR (1) BR112014000792A2 (enExample)
CA (1) CA2841932A1 (enExample)
CO (1) CO6880065A2 (enExample)
CR (1) CR20140071A (enExample)
DO (1) DOP2014000012A (enExample)
EA (1) EA201490272A1 (enExample)
ES (1) ES2548513T3 (enExample)
IL (1) IL230430A0 (enExample)
MA (1) MA35342B1 (enExample)
MX (1) MX2014000536A (enExample)
PH (1) PH12014500126A1 (enExample)
TN (1) TN2014000016A1 (enExample)
WO (1) WO2013008217A1 (enExample)
ZA (1) ZA201400374B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Kras g12c之共價抑制劑
HUE037134T2 (hu) * 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
CA2922469A1 (en) 2013-09-11 2015-03-19 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN105793264B (zh) * 2014-03-10 2017-09-01 四川海思科制药有限公司 取代的二氢苯并呋喃‑哌啶‑甲酮衍生物、其制备及用途
RU2016147727A (ru) 2014-05-07 2018-06-08 Мерк Патент Гмбх Гетероциклилбутанамидные производные
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
CA3003600A1 (en) * 2015-11-02 2017-05-11 Merck Patent Gmbh 1,4-dicarbonyl-piperidyl derivatives
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP2022510368A (ja) 2018-12-03 2022-01-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング タンキラーゼのインヒビターとしての4-ヘテロアリールカルボニル-n-(フェニルまたはヘテロアリール)ピペリジン-1-カルボキサミド
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
US20240041859A1 (en) * 2020-12-03 2024-02-08 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
EP1142881A4 (en) 1999-01-14 2003-05-07 Meiji Seika Kaisha POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
KR100663147B1 (ko) 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
CA2568835C (en) * 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE602006015658D1 (de) 2005-06-27 2010-09-02 Amgen Inc Entzündungshemmende arylnitrilverbindungen
EP2021337B1 (en) * 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
AU2008324203A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
US9181266B2 (en) * 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Also Published As

Publication number Publication date
US20150126513A1 (en) 2015-05-07
WO2013008217A1 (en) 2013-01-17
MA35342B1 (fr) 2014-08-01
BR112014000792A2 (pt) 2017-10-31
ZA201400374B (en) 2014-10-29
TN2014000016A1 (en) 2015-07-01
AP2014007400A0 (en) 2014-01-31
JP5957077B2 (ja) 2016-07-27
CA2841932A1 (en) 2013-01-17
CO6880065A2 (es) 2014-02-28
EA201490272A1 (ru) 2014-05-30
NZ620426A (en) 2015-08-28
MX2014000536A (es) 2014-12-05
EP2731940A1 (en) 2014-05-21
CN103797006A (zh) 2014-05-14
AU2012282076A1 (en) 2014-02-27
US9163003B2 (en) 2015-10-20
IL230430A0 (en) 2014-03-31
JP2014522855A (ja) 2014-09-08
USRE46942E1 (en) 2018-07-10
KR20140051944A (ko) 2014-05-02
CN103797006B (zh) 2016-01-27
CR20140071A (es) 2014-10-16
PH12014500126A1 (en) 2014-02-24
DOP2014000012A (es) 2014-07-31
EP2731940B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
EP2731940B1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EP2731942B1 (en) Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
AU2007311591B2 (en) Biaryl ether urea compounds
AU2009311756B2 (en) Modulators of amyloid beta.
JP2021515767A (ja) Erk5阻害剤の同定及び使用
EA032416B1 (ru) Соединения триазолопиримидина и их применения
UA109438C2 (uk) Азотні гетероциклічні сполуки, які застосовуються як інгібітори pde10
WO2005105814A1 (en) Tetracyclic inhibitors of janus kinases
WO2016102493A1 (en) Imidazopyridine ezh2 inhibitors
US9546173B2 (en) Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
WO2025163390A2 (en) Heterobifunctional compounds for the degradation of hpk1
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors
NZ620426B2 (en) 4-piperidinyl compounds for use as tankyrase inhibitors
NZ728416B2 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
NZ728416A (en) 2-(morpholin-4-yl)-1,7-naphthyridines